Key result
Thromboprophylaxis with low molecular weight heparin, heparin, or fondaparinux significantly reduces the rate of venous thromboembolism in high-risk hospitalized medical patients.
Why the study?
Does thromboprophylaxis with low molecular weight heparin, heparin, or fondaparinux reduce venous thromboembolism in hospitalized patients with cancer?
Does thromboprophylaxis with low molecular weight heparin, heparin, or fondaparinux reduce venous thromboembolism in hospitalized patients with cancer?
Guidelines support the use of thromboprophylaxis in hospitalized patients with cancer to reduce the risk of venous thromboembolism, provided there is no active bleeding or high bleeding risk.
Answers are grounded in this paper and cite their sources.
Supports thromboprophylaxis in high-risk cancer inpatients per guidelines; leaves open optimal agent, duration, and bleeding-risk tailoring.
This is a literature review of the frequency of venous thromboembolism in hospitalized patients with cancer and of the available evidence supporting the use of thromboprophylaxis. Patients with cancer are at particularly high risk of venous thromboembolism and account for almost 20% of patients in the population. Hospitalization is an important risk factor in patients with cancer, with rates reported between 0.6% and 7.8%. The incidence has been increasing over the past decade. Three randomized controlled trials and meta-analyses indicate that prophylaxis with low molecular weight heparin, heparin, or fondaparinux significantly reduces the rate of venous thromboembolism in hospitalized medical patients who are at high risk. Patients with cancer were included in these studies, but prospective trials specifically focused on patients with cancer are not available. Evidence indicates that appropriate thromboprophylaxis is provided to a minority of hospitalized patients with cancer and that targeted educational efforts and computerized prompt systems can increase appropriate use. Guidelines developed by both oncology and thrombosis organizations support the use of thromboprophylaxis in hospitalized patients with cancer. In conclusion, most patients hospitalized with cancer are at high risk of venous thromboembolism, and thromboprophylaxis should be provided in the absence of active bleeding or a high bleeding risk.
No takes yet. Share an insight, caveat, or question.
Charles W. Francis (2009) conducted a review in Venous thromboembolism in hospitalized patients with cancer. Thromboprophylaxis (low molecular weight heparin, heparin, or fondaparinux) was evaluated on Venous thromboembolism. Thromboprophylaxis with low molecular weight heparin, heparin, or fondaparinux significantly reduces the rate of venous thromboembolism in high-risk hospitalized medical patients.
Synapse has enriched 10 related papers. Consider them for comparative context: